A Randomized Trial Comparing Intensified CNOP vs. CHOP in Patients with Aggressive Non-Hodgkin's Lymphoma

The standard CHOP regimen may cure 30-40% of patients with advanced aggressive non-Hodgkin's lymphoma (ANHL). Mitoxantrone is an anthracenedione, which is active in NHL and its toxicity profile may be more favorable than doxorubicin with respect to alopecia, mucositis and cardiotoxicity. This study was designed to compare the effectiveness of an escalated dose of mitoxantrone with that of standard doxorubicin, used in the CHOP regimen in patients with ANHL. One hundred and forty three eligible patients with ANHL were randomized to receive 6 cycles of either CHOP (n =71) or intensified CNOP (iCNOP) (n =72), with mitoxantrone 20 mg/m 2, i.v., d.1 instead of doxorubicin. Complete responders (CR) were again randomized either to receive interferon- α (IFN- α ) maintenance (3 MU t.i.w., s.c.) or not. The CR rate was 70 vs. 76% for iCNOP and CHOP (p =0.45), and the overall response rate was 81 vs. 83%, respectively (p =0.71). The 5-year failure free survival (FFS) was 48 and 50% in the iCNOP and CHOP arm, respectively (p =0.45), and the 5-year overall survival (OS) was 61 vs. 64% (p =0.56). IFN- α did not prolong relapse free survival (p =0.91). iCNOP produced less alopecia (p =0.001) but more febrile episodes (p =0.04) than CHOP, while requiring more frequent G-CSF support (p =0.01). Two cases of acute myelogenous leukemia (AML) were recorded, both in the iCNOP arm (p =0.14). In conclusion, iCNOP was equally effective to CHOP in patients with ANHL, producing more leukopenia and febrile episodes, but less alopecia. The development of two cases of secondary AML in the iCNOP arm is of concern.